Isracann Biosciences Stock Today

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 88

 
High
 
Low
Very High
Isracann Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Isracann Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada. Isracann Biosciences is traded on OTC Exchange in the United States. The company has 175.99 M outstanding shares. More on Isracann Biosciences

Moving against Isracann Pink Sheet

  0.82GLABF Gemina LaboratoriesPairCorr
  0.58AXP American Express Fiscal Year End 24th of January 2025 PairCorr
  0.54PLTR Palantir Technologies Aggressive PushPairCorr
Isracann Biosciences cannot be verified against its exchange. It appears that Isracann Biosciences is not available for investing at the moment. Please verify the symbol is currently traded on PINK Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Refresh

Isracann Pink Sheet Highlights

Business ConcentrationDrug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Isracann Biosciences [ISCNF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Isracann Biosciences's market, we take the total number of its shares issued and multiply it by Isracann Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Isracann Biosciences classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 175.99 M outstanding shares. Isracann Biosciences has accumulated about 310.61 K in cash with (1.75 M) of positive cash flow from operations.
Check Isracann Biosciences Probability Of Bankruptcy

Isracann Stock Against Markets

Try Other Suggestions

ISC ARCELORMITSAADR 1RC 1CompanyDelisted
ISCO International Stem CellOTC Stock
ISCSX Vy Umbia ContrarianMutual Fund
ISCB iShares Morningstar Small CapETF

Be your own money manager

Our tools can tell you how much better you can do entering a position in Isracann Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bollinger Bands Now

   

Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Module

Isracann Biosciences Corporate Management

Other Information on Investing in Isracann Pink Sheet

Isracann Biosciences financial ratios help investors to determine whether Isracann Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isracann with respect to the benefits of owning Isracann Biosciences security.